YONKERS, N.Y., Aug. 29, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and...
AWG Member News
SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences READ FULL TEXT
ContraFect to Present at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
YONKERS, New York, Aug. 22, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery...
Motif Bio to Present Iclaprim Data at ESCMID/ASM Conference
NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing...
ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections
YONKERS, N.Y., Aug. 14, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and...
Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections
PDUFA action date set for February 13, 2019 NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/NASDAQ:...
SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update
SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update READ FULL TEXT
ContraFect Announces Second Quarter 2018 Financial Results
YONKERS, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and...
Motif Bio to Present at Investor Events in August and September
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing...
Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037
NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/NASDAQ: MTFB) (“Motif Bio” or the “Company”), a clinical-stage...
Aridis Pharmaceuticals Launches Proposed Initial Public Offering
San Jose, CA—August 6, 2018 – Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of targeted...
ContraFect Corporation Prices $10 Million Public Offering of Common Stock
YONKERS, N.Y., July 27, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a biotechnology company focused on the discovery and development...